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Background: The aim of this study was to evaluate the prognostic value of the number of negative lymph nodes
(NLNs) in breast cancer patients after mastectomy.
Methods: 2,455 breast cancer patients who received a mastectomy between January 1998 and December 2007
were retrospectively reviewed. The prognostic impact of the number of NLNs with respect to disease-free survival
(DFS) was analyzed.
Results: The median follow-up time was 62.0 months, and the 5-year and 10-year DFS was 87.1% and 74.3%,
respectively. The DFS of patients with >10 NLNs was significantly higher than that of patents with ≤10 NLNs, and
the 5-year DFS rates were 87.5% and 69.5%, respectively (P < 0.001). Univariate Cox analysis showed that the NLN
count (continuous variable) was a prognostic factor of DFS (hazard ratio [HR] = 0.913, 95% confidence interval [CI]:
0.896-0.930, P < 0.001). In multivariate Cox analysis, patients with a higher number of NLNs had a better DFS
(HR = 0.977, 95% CI: 0.958-0.997, P = 0.022). Subgroup analysis showed that the NLN count had a prognostic value in
patients at different pT stages and pN positive patients (log-rank P < 0.001). However, it had no prognostic value in
pN0 patients (log-rank P = 0.684).
Conclusions: The number of NLNs is an independent prognostic factor of DFS in breast cancer patients after
mastectomy, and patients with a higher number of NLNs have a better DFS.
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Though the survival rates of patients receiving sentinel
lymph node biopsy and of patients receiving axillary
lymph node dissection are similar in a certain specific
populations with breast cancer [1,2], and sentinel lymph
node biopsy can decrease postoperative arm lymph-
edema [3,4], the axillary lymph node status is still one of
the most important prognostic indicators of breast can-
cer patients and is useful for guiding treatment. More-
over, it is also important in the Union for International
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Axillary lymph node dissection is an important
method for determining the axillary lymph node status
in breast cancer patients. In theory, the survival of breast
cancer patients is improved by removing more axillary
lymph nodes. However, the prognostic value of the num-
ber of axillary lymph nodes removed is controversial
[5-7]. Because both positive and negative lymph nodes
are removed, it is difficult to accurately determine the
proper number of lymph nodes that should be removed.
The number of negative lymph nodes (NLNs) removed
is obtained by subtracting the number of positive lymph
nodes from the total number of removed lymph nodes.
Because removing more NLNs may reduce the possibil-
ity of occult lesions and thus improve the prognosis, theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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degree of the appropriateness of axillary lymph node dis-
section. The prognostic value of the number of NLNs
removed in esophageal cancer, colorectal cancer, and
cervical cancer has been proven [8-11]. However, there
have been few studies on its prognostic value of the
number of NLNs removed for breast cancer [12,13]. The
purpose of this study was to determine the prognostic
value of the number of NLNs with respect to disease-
free survival (DFS) of breast cancer patients after
mastectomy.Methods
Patients
The records of breast cancer patients treated at Sun Yat-
Sen University Cancer Center between January 1998 and
December 2007 were retrospectively reviewed. The in-
clusion criteria were: 1) Females who had histologically
confirmed unilateral invasive breast cancer; 2) Under-
went mastectomy together with axillary lymph node dis-
section and the number of removed axillary lymph
nodes was more than 10; 3) The tumor was completely
removed and the margins were negative; 4) No neoadju-
vant chemotherapy was administered before surgery and
postoperative treatments including chemotherapy, radio-
therapy, and endocrine therapy were performed based
on the tumor stage and hormone receptor status. The
study was approved by the ethics committee of Sun Yat-
Sen University Cancer Center. All patients provided
written consent for storage of their information in the
hospital database, and for use of this information for re-
search purposes.Clinicopathologic factors and lymph node status
The risk of recurrence was evaluated according to the
clinicopathological characteristics and immunohisto-
chemical factors which included age, menopause status,
pT stage, pN stage, and estrogen receptor (ER), proges-
terone receptor (PR), and human epithelial growth factor
receptor family 2 (Her2) status. ER and PR positive was
defined as more than 1% positive cells on immunohisto-
chemical analysis. Her2-positivity was defined as a 3+
immunohistochemical result or a 2+ immunohistochem-
ical result confirmed by fluorescent in situ hybridization
(FISH). pT stage and pN stage were consistent with the
UICC/AJCC TNM classification (7th Edition), and pN
stages were defined as follows: pN0, no regional lymph
node metastasis identified histologically; pN1, metastasis
in 1–3 lymph nodes; pN2, metastasis in 4–9 lymph
nodes; pN3, metastasis in ≥10 lymph nodes. The number
of removed NLNs was defined as the number of positive
lymph nodes subtracted from the total number of re-
moved lymph nodes.Histopathological examination of resected lymph nodes
All resected specimens were submitted for pathologic
examination. Pathologists examined all slides to evaluate
the depth of the primary tumors and node involvement,
which were separately labeled by the surgeons in a rou-
tine manner. One section from each lymph node was
analyzed after hematoxylin and eosin (H&E) staining.
Lymph nodes that were examined included those that
were embedded in the en bloc specimen and not labeled
by surgeons, but were identified by the pathologists. The
lymph node number was counted on low-power field
microscopy. The total number of resected lymph nodes
was the sum of the lymph nodes removed form the ax-
illa. The number of metastatic lymph nodes, and the
number of removed nodes was determined.
Follow-up and survival endpoints
Follow up was performed 3–6 months after surgery by
hospital visit, telephone, or mail correspondence. Be-
cause all patients in the present study received adjuvant
treatment according to the stage and hormone receptor
status, the endpoint was DFS. For patients with recur-
rence, survival time was determined from the date of
surgery to the date of locoregional recurrence and/or
distant metastasis.
Statistical analysis
The χ2 and Fisher’s exact tests were used to analyze the
differences between qualitative data. Recognizing that
the total number of NLNs removed may be subjected to
incomplete counting or natural interindividual variation
in nodal distribution, the variable was examined as a cat-
egorical variable based on quartiles. Calculation of sur-
vival rates were plotted by the Kaplan-Meier method,
and compared using the log-rank test. Univariate and
multivariate Cox regression model analyses were per-
formed. All analyses were performed using the SPSS
statistical software package version 16.0 (IBM Corpor-
ation, Armonk, NY, USA). A value of P < 0.05 was con-
sidered statistically significant.
Results
Clinicopathological characteristics and lymph node
dissection data
A total of 2,455 patients were included in the analysis,
and the clinical features are shown in Table 1. The me-
dian number of removed lymph nodes was 15 (25th per-
centile = 12, 75th percentile = 18; range, 10–73), 1,263
patients were node negative (51.4%), and 1,192 patients
were node positive (48.6%). Of the patients, 769, 207
and 216 were pN1, pN2 and pN3, respectively.
The median number of NLNs removed was 13 (25th
percentile = 11, 75th percentile = 16; range, 0–40). Exam-
ination of the number of NLNs removed as a categorical
Table 1 Correlation between the number of negative lymph nodes removed and clinicopathologic factors
Characteristic Number of negative lymph nodes P value
0-10 (n = 607) 11-13 (n = 706) 14-16 (n = 554) 17-40 (n = 588)
Age
<35 234 68 (11.2) 51 (7.2) 51 (9.2) 64 (10.9) 0.054
≥35 2221 539 (88.8) 655 (92.8) 503 (90.8) 524 (89.1)
Menopause
Premenopause 1641 402 (66.2) 460 (65.2) 354 (63.9) 425 (72.3) 0.012*
Postmenopause 814 205 (33.8) 246 (34.8) 200 (36.1) 163 (27.7)
pT stage
T1 812 159 (26.2) 259 (36.7) 190 (34.3) 204 (34.7) <0.001*
T2 1428 352 (58.0) 398 (53.4) 323 (58.3) 355 (60.4)
T3 155 71 (11.7) 41 (5.8) 25 (4.5) 18 (3.1)
T4 60 25 (4.1) 8 (1.1) 16 (2.9) 11 (1.8)
pN stage
N0 1263 120 (19.8) 430 (60.9) 342 (61.7) 371 (63.1) <0.001*
N1 769 185 (30.5) 220 (31.2) 174 (31.4) 190 (32.3)
N2 207 115 (18.9) 44 (6.2) 30 (5.4) 18 (3.1)
N3 216 187 (30.8) 12 (1.7) 8 (1.5) 9 (1.5)
ER
Negative 953 245 (40.4) 252 (35.7) 219 (39.5) 237 (40.3) 0.304
Positive 1292 321 (52.9) 384 (54.3) 287 (51.8) 300 (51.0)
Unknown 210 41 (6.7) 70 (10.0) 48 (8.7) 51 (8.7)
PR
Negative 824 207 (34.1) 223 (31.5) 198 (35.7) 196 (33.3) 0.398
Positive 1421 359 (59.1) 413 (58.5) 308 (55.6) 341 (58.0)
Unknown 210 41 (6.8) 70 (10.0) 48 (8.7) 51 (8.7)
Her-2
Negative 1377 329 (54.2) 395 (56.0) 307 (55.4) 346 (58.8) 0.460
Positive 666 168 (27.7) 183 (25.9) 157 (28.3) 158 (26.9)
Unknown 412 110 (18.1) 128 (18.1) 90 (16.3) 84 (14.3)
Data are presented as number (percentage).
ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor-2.
*P < 0.05 indicates a significant difference.
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tients with 0–10 NLNs removed (group 1) was 607, the
number with 11–13 NLNs removed (group 2) was 706,
the number with 14–16 NLNs removed (group 3) was
554, and the number with 17–40 NLNs removed (group
4) was 588.
The NLN count was associated with menopause sta-
tus, pT stage, and pN stage (P < 0.05). The NLN count
was not associated with age or ER, PR, and Her-2 status
(all, P > 0.05) (Table 1).
Relationship between the number of NLNs removed and
DFS
The median follow-up time was 62.0 months (range, 6
to 158 months), and 477 patients had local recurrenceand/or distant metastasis. The 5- and 10-year DFS rates
were 81.7% and 74.3%, respectively. The number of
NLNs removed had a significant impact on DFS, the 5-
year DFS in group 1, group 2, group 3, and group 4 were
69.5%, 86.0%, 83.3%, and 87.6%, respectively. The 10-
year DFS in group 1, group 2, group 3, and group 4 were
61.8%, 76.8%, 78.5%, and 81.7%, respectively (P < 0.001)
(Figure 1A). However, intersection and overlapping were
observed between the survival curves of patients in
group 2, 3 and 4; therefore, we combined these 3 groups.
The analysis with these groups combined showed that
the 5- and 10-year DFS rates were 85.7% and 78.5% in
patients with > 10 NLNs removed, which were signifi-
cantly higher than 69.5% and 61.8% of patients with ≤ 10
NLNs removed (P < 0.001) (Figure 1B).
Figure 1 Impact of the number of negative lymph nodes on disease-free survival for 4 categories of patients (A), and patients with
group 1 vs. group 2-4 (B).
Table 2 Univariate and multivariate analyses of disease-free survival
Characteristic Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age
<35 1 1
≥35 0.618 0.476-0.803 <0.001* 0.679 0.522-0.883 0.004*
Menopause
Premenopause 1 —
Postmenopause 0.995 0.822-1.205 0.960 —
pT stage
T1 1 1
T2 1.699 1.361-2.120 <0.001* 1.361 1.088-1.704 0.007*
T3 2.844 2.036-3.972 <0.001* 1.585 1.116-2.252 0.010*
T4 3.150 1.933-5.134 <0.001* 1.798 1.091-2.963 0.021*
pN stage
N0 1 1
N1 2.187 1.746-2.740 <0.001* 2.083 1.658-2.616 <0.001*
N2 3.139 2.322-4.244 <0.001* 2.506 1.817-3.456 <0.001*
N3 6.725 5.236-8.638 <0.001* 4.575 3.315-6.313 <0.001*
ER
Negative 1 1
Positive 0.586 0.504-0.682 <0.001* 0.720 0.582-0.892 0.003*
PR
Negative 1 1
Positive 0.620 0.533-0.722 <0.001* 0.790 0.636-0.980 0.032*
Her2
Negative 1 —
Positive 0.977 0.871-1.096 0.693 —
Number of NLNs (continuous variable) 0.913 0.896-0.930 <0.001* 0.977 0.958-0.997 0.022*
DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ER estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor
receptor-2; NLNs, negative lymph nodes.
*P < 0.05 indicates a significant difference.
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Univariate analysis showed that age, pT stage, pN stage,
ER status, PR status, and the number of NLNs removed
(continuous variables) were prognostic factors affecting
DFS (all, P < 0.001) (Table 2).
Multivariate analysis showed that the number of NLNs
removed was an independent prognostic factor of DFS;
patients with a higher number of NLNs had a better
DFS (hazard ratio [HR] = 0.977, 95% confidence interval
[CI]: 0.958-0.997, P = 0.022). In addition, age, pT stage,
pN stage, ER status, and PR status were also independ-
ent risk factors of DFS (all, P < 0.05) (Table 2).
Impact of the number of NLNs removed on DFS by pT
stage
Subgroup analysis of the impact of the number of NLNs
removed on DFS by different pT stage showed that pa-
tients with a higher number of NLNs removed at all pT
stages had better DFS (log-rank P < 0.001 for pT1, P <
0.001 for pT2, P < 0.001 for pT3, and P < 0.001 for pT4)
(Figure 2A-D).
Impact of the number of NLNs removed on DFS by pN
stage
Subgroup analysis of the impact of the number of NLNs
removed on DFS by different pN stage showed that the
NLN count removed had no impact on DFS in pN0 pa-
tients (log-rank P = 0.684). However, a higher number of
NLNs removed indicated better DFS in pN-positive pa-
tients (log-rank P < 0.001) (Figure 3A,B).
Discussion
In the present study, we investigated the impact of the
number of NLNs removed after mastectomy in breast
cancer patients and found that the number of NLNs re-
moved was an independent prognostic factor of DFS. Pa-
tients with a higher number of NLNs removed had
better DFS, and the number of NLNs had a prognostic
value in patients with different pT stages and in pN-
positive patients.
Because lymph node dissection includes positive
lymph nodes, it is difficult to accurately estimate theFigure 2 Impact of the number of negative lymph nodes on the diseaappropriate number of lymph nodes to remove. Our re-
sults are consistent with those of other studies which have
examined the prognostic value of the number of NLNs re-
moved in breast cancer patients [12,13]. Karlsson et al.
found that the number of NLNs removed was an inde-
pendent factor affecting prognosis; patients with ≥ 10
NLNs removed had a better prognoses than patients
with <10 NLNs removed, which affected node positive
patients but not node negative patients [12]. Kuru re-
ported that patients with >15 NLNs removed had a bet-
ter prognoses than those with fewer removed [13]. The
mechanism underlying why the number of NLNs can
be used to predict the survival of breast cancer patients
is unclear. Insufficient lymph node dissection may re-
sult in inaccurate lymph node staging, and removing
more lymph nodes makes for more accurate determin-
ation of the lymph node status. Therefore, studies have
proposed the “stage migration” hypothesis that obtain-
ing accurate information of lymph nodes and determin-
ing the lymph node stage by removing more lymph
nodes to decrease the probability of error of nodal
stage. Schaapveld et al. found that removing more
lymph nodes resulted in a better survival, which sup-
ports the “stage migration” hypothesis [14].
At present, H&E staining is a commonly used method
for detecting positive lymph nodes. However, immuno-
histochemical methods can reveal occult lesions in
lymph nodes [15,16]. It is obvious that an increased
number of NLNs removed increases the potential for the
identification of micrometastases. Because immunohisto-
chemical methods were not used for examination of the
lymph nodes in the present study, removing a higher
number of NLNs might eliminate some potential
remnant lesions, and this can explain the fact that pa-
tients with a higher number of NLNs removed had bet-
ter DFS in the present study, which also supports the
“stage migration” hypothesis. Moreover, it should be
mentioned that the number of NLNs removed may be
related to the host immune response against tumor cells,
and the molecular biology of tumor cells [17,18]. A
study examining colorectal cancers showed there was a
significant correlation between lymphocyte responsese-free survival of pT1 (A), pT2 (B), pT3 (C), and pT4 (D) patients.
Figure 3 Impact of the number of negative lymph nodes on the disease-free survival of pN0 patients (A) and pN positive patients (B).
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is meaningful to further investigate the number of NLNs
removed and the lymphocyte response against tumor
cells for the individualized treatment of breast cancer.
The American College of Surgeons Oncology Group
(ACOSOG) Z0011 trial showed that the local recurrence
and survival rates of patients who underwent breast-
conserving surgery with negative sentinel lymph node or
1–2 positive sentinel lymph nodes were not affected by
whether axillary lymph node dissection was performed
or not, and thereby suggests that axillary lymph node
dissection should not be carried out for these patients
[1,2]. However, the report of the St-Gallen International
Breast Cancer Conference in 2013 indicates that axillary
lymph node dissection should be performed for patients
who cannot receive radiotherapy or who have ≥ 3 meta-
static sentinel lymph nodes [20]. Z0011 trial participants
received breast conserving surgery and radiotherapy, pa-
tients enrolled in the present study were treated with
mastectomy and irradiation was performed based on the
tumor stage and lymph node status.
In the present study, subgroup analysis showed that
the number of NLNs removed only affected the DFS of
node positive patients. Though it was reported that the
number of removed lymph nodes might affect the local
recurrence rate of node positive patients [21], we found
that the number of NLNs removed did not affect the
DFS of pN0 patients and thus consider that sentinel
lymph node biopsy is sufficient for the determination of
lymph node status in node-negative patients.
There are limitations of the present study that must be
considered. First, the study was a single center retro-
spective study, and thus may not represent the majority
of the population. However, the number of cases was
large. Second, the optimal number of NLNs removed is
not consistent with that of other studies. This may be re-
lated to differences in clinical data and surgical proce-
dures, and prospective multicenter studies should becarried out to identify an exact value and a more appro-
priate cut-off number of the NLNs that should be
removed.
Conclusions
In conclusion, our study indicates that the number of
NLNs removed is an important factor affecting the DFS
of breast cancer patients after mastectomy, and patients
with a higher number of NLNs removed have a better
prognosis. However, our result should be verified by fur-
ther studies, and the related mechanism should be stud-
ied to provide a choice for the postoperative treatment
of breast cancer.
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